Open Interest and Volume Dynamics
The latest data reveals that Lupin's open interest in derivatives rose sharply to 30,025 contracts, up 11.98% from the previous figure of 26,813. This increase of 3,212 contracts underscores a growing commitment from traders and investors in the futures and options market. Concurrently, the volume stood at 25,456 contracts, indicating active trading and liquidity in the stock's derivatives.
In monetary terms, the futures segment accounted for a value of approximately ₹23,822.76 lakhs, while the options segment's value was substantially higher at ₹23,597.96 crores, culminating in a total derivatives market value of ₹27,730.48 lakhs. This substantial derivatives activity reflects heightened interest and potential positioning ahead of anticipated price movements.
Price Performance and Technical Indicators
Lupin's underlying share price closed at ₹2,351, marking a 0.67% gain on the day and outperforming its sector by 0.31%. Notably, the stock has recorded gains over the past two consecutive sessions, delivering a cumulative return of 1.92%. It is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong bullish trend and technical strength.
Investor participation has also surged, with delivery volumes reaching 10.96 lakh shares on 5 March, an 86.81% increase compared to the five-day average delivery volume. This rise in delivery volume suggests genuine accumulation rather than speculative trading, reinforcing the positive price momentum.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Market Positioning and Directional Bets
The surge in open interest combined with rising volumes suggests that market participants are positioning for a sustained upward move in Lupin's stock price. The increase in futures and options activity often precedes significant price action, as traders establish directional bets through leveraged instruments.
Given Lupin's recent upgrade in its Mojo Grade from Strong Buy to Buy on 16 February 2026, with a Mojo Score of 78.0, the market appears to be factoring in a slightly more cautious but still positive outlook. The company’s market capitalisation stands at ₹1,07,725 crore, categorising it as a mid-cap stock with ample liquidity and institutional interest.
Despite the slight downgrade in rating, Lupin’s fundamentals remain robust, supported by consistent earnings growth and a strong product pipeline in the Pharmaceuticals & Biotechnology sector. The stock’s ability to outperform the sector and the Sensex, which declined by 0.70% on the same day, further highlights its relative strength.
Liquidity and Trading Considerations
Lupin's liquidity profile is solid, with the stock capable of handling trade sizes up to ₹5.23 crore based on 2% of the five-day average traded value. This level of liquidity is favourable for institutional investors and large traders seeking to enter or exit positions without significant market impact.
The rising delivery volumes and sustained price gains over multiple sessions indicate that the stock is attracting genuine investor interest rather than speculative momentum. This bodes well for the sustainability of the current uptrend and reduces the risk of abrupt reversals.
Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Outlook and Investor Implications
With Lupin Ltd. demonstrating strong technical and fundamental signals, investors should consider the implications of the rising open interest and volume patterns. The derivatives market activity suggests that traders are increasingly confident in the stock’s upward trajectory, potentially anticipating positive news flow or sector tailwinds.
However, the slight downgrade in the Mojo Grade from Strong Buy to Buy indicates a need for cautious optimism. Investors should monitor upcoming earnings releases, regulatory developments, and sector dynamics closely to validate the sustainability of the current momentum.
Given the stock’s mid-cap status and robust liquidity, it remains an attractive option for both long-term investors and active traders seeking exposure to the Pharmaceuticals & Biotechnology sector. The recent price action and market positioning reinforce Lupin’s status as a key player poised for continued growth.
Summary
Lupin Ltd.’s recent surge in open interest by nearly 12%, coupled with rising volumes and a new 52-week high, signals strong market conviction in the stock’s bullish potential. Trading above all major moving averages and outperforming its sector and the Sensex, Lupin is attracting increased investor participation and directional bets in the derivatives market. While the Mojo Grade adjustment suggests a tempered outlook, the company’s fundamentals and liquidity profile support a positive investment case. Market participants should remain vigilant to evolving market conditions but can view Lupin as a compelling opportunity within the Pharmaceuticals & Biotechnology space.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
